Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma
暂无分享,去创建一个
Michael A S Jewett | B. Gallie | M. Ohh | R. Hill | M. Jewett | M. Gervais | Brenda L Gallie | Richard P Hill | Michael Ohh | Arthy Saravanan | Michelle L Gervais | Pauline C Henry | T Nadine Burry | Andrew J Evans | A. Evans | P. Henry | A. Saravanan | T. Burry | Michelle L Gervais | Pauline C Henry | Brenda L Gallie | Michael A S Jewett | Richard P Hill | Andrew J Evans
[1] E. Voest,et al. Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain* , 2005, Journal of Biological Chemistry.
[2] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[3] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[4] W. Jiang,et al. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] A. Marx,et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .
[6] Kazuki Kobayashi,et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.
[7] P. Rehak,et al. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases , 2004, Modern Pathology.
[8] K. Moon,et al. Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. , 2006, Archives of pathology & laboratory medicine.
[9] B. de Strooper,et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Malpica,et al. C-met proto-oncogene expression in benign and malignant human renal tissues. , 1997, The Journal of urology.
[11] B. Curti. Renal cell carcinoma. , 2004, JAMA.
[12] S. Serra,et al. Nuclear expression of E-cadherin. , 2008, The American journal of surgical pathology.
[13] W. Kaelin,et al. Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.
[14] W. Kaelin,et al. Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity , 2002, Molecular and Cellular Biology.
[15] Ying Huang,et al. Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.
[16] J. Frydman,et al. The Hsp70 and TRiC/CCT Chaperone Systems Cooperate In Vivo To Assemble the Von Hippel-Lindau Tumor Suppressor Complex , 2003, Molecular and Cellular Biology.
[17] Mirna Lechpammer,et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.
[18] M. Ohh,et al. The Role of VHL in the Regulation of E-Cadherin: A New Connection in an Old Pathway , 2007, Cell cycle.
[19] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[20] G. Semenza,et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.
[21] W. H. Porter,et al. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer , 1999, British Journal of Cancer.
[22] C. Damsky,et al. Soluble 80‐kd fragment of cell‐CAM 120/80 disrupts cell‐cell adhesion , 1987, Journal of cellular biochemistry.
[23] I. Sesterhenn,et al. World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .
[24] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. Comoglio,et al. Overexpression of the met/HGF receptor in renal cell carcinomas , 1996, International journal of cancer.
[26] W. Kaelin,et al. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] K. Pienta,et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] W. Kaelin,et al. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.
[29] R. Burk,et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[31] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[32] R. Kemler,et al. Presenilin-dependent processing and nuclear function of gamma-protocadherins. , 2005, The Journal of biological chemistry.
[33] Sarah K. Johnson,et al. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E‐cadherin , 2007, Cancer.
[34] M. Ohh,et al. Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] R. Nusse,et al. Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.
[36] M. Mareel,et al. Plasmin Produces an E-Cadherin Fragment That Stimulates Cancer Cell Invasion , 2002, Biological chemistry.
[37] M. Jewett,et al. Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma , 2005 .
[38] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[39] Y. Doki,et al. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. , 1998, British Journal of Cancer.
[40] B. Rini,et al. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.
[41] I. Shih,et al. Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .
[42] G. Serban,et al. A presenilin‐1/γ‐secretase cleavage releases the E‐cadherin intracellular domain and regulates disassembly of adherens junctions , 2002, The EMBO journal.
[43] M. Nakao,et al. Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell – cell contacts , 1999, Oncogene.
[44] Richard D Klausner,et al. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. , 2002, Cancer research.
[45] P. Lara,et al. Renal cell carcinoma: current status and emerging therapies. , 2007, Cancer treatment reviews.
[46] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[47] O. Huber,et al. Cleavage and Shedding of E-cadherin after Induction of Apoptosis* , 2001, The Journal of Biological Chemistry.
[48] R. Raval,et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.
[49] K. Nakagawa,et al. Soluble E-cadherin fragments increased in circulation of cancer patients. , 1994, British Journal of Cancer.
[50] G. Berx,et al. VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail , 2006, Molecular and Cellular Biology.
[51] D. Fishman,et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. , 2007, Cancer research.
[52] B. Seizinger,et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.
[53] H. Kawamata,et al. Biological role of HGF/MET pathway in renal cell carcinoma. , 1999, The Journal of urology.
[54] G. Carpenter. Nuclear localization and possible functions of receptor tyrosine kinases. , 2003, Current opinion in cell biology.
[55] R. Klausner,et al. The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.
[56] Y. Nagashima,et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. , 2006, Cancer research.
[57] A. P. Soler,et al. Nuclear localization of E-cadherin expression in Merkel cell carcinoma. , 2000, Archives of pathology & laboratory medicine.
[58] M. Fortini,et al. Signalling: γ-Secretase-mediated proteolysis in cell-surface-receptor signalling , 2002, Nature Reviews Molecular Cell Biology.
[59] P. Troncoso,et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.
[60] Tian-Li Wang,et al. Notch signaling, gamma-secretase inhibitors, and cancer therapy. , 2007, Cancer research.
[61] W. Kaelin,et al. The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.
[62] E. Choi,et al. Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells , 2007, European Surgical Research.
[63] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[64] V. Thulasiraman,et al. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. , 1999, Molecular cell.
[65] R. Kemler,et al. Presenilin-dependent Processing and Nuclear Function of γ-Protocadherins* , 2005, Journal of Biological Chemistry.
[66] J. Patard,et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] J. Joyce,et al. Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.
[68] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[69] E. Choi,et al. Change of E-Cadherin by Hepatocyte Growth Factor and Effects on the Prognosis of Hypopharyngeal Carcinoma , 2007, Annals of Surgical Oncology.
[70] B. Gumbiner,et al. Regulation of Cadherin Adhesive Activity , 2000, The Journal of cell biology.
[71] R. Nusse,et al. Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.
[72] P. Saftig,et al. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. , 2006, Pharmacology & therapeutics.